Cited by 5,761Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Open access

Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H.·2006·New England Journal of Medicine

DOI 10.1056/nejmoa061884

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa061884

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citation
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,985

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 4

Brown LF, 1993, Cancer Res, 53, 4727
Kabbinavar FF, 1995, Proc Am Assoc Cancer Res, 36, 488
Borgstrom P, 1999, Anticancer Res, 19, 4203
Miller KD, 2005, Breast Cancer Res Treat, 94, S6

Sorted by citations

Items 401–500 of 1,018

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Šeruga, B., Ocaña, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 174
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
Durães, C., Almeida, G. M., Seruca, R., Oliveíra, C., & Carneiro, F. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1533-y · Cited by 171
Role of myeloid cells in tumor angiogenesis and growth
Shojaei, F., Zhong, C., Wu, X., Yu, L., & Ferrara, N. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.06.003 · Cited by 169
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2346 · Cited by 167
Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung Cancer
Aftab, B. T., Dobromilskaya, I., Liu, J. O., & Rudin, C. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0691 · Cited by 167
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
Johnson, F. M., Bekele, B. N., Feng, L., Wistuba, I. I., Tang, X., Tran, H. T., Erasmus, J. J., Hwang, L.-L., Takebe, N., Blumenschein, G. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5474 · Cited by 167
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Johnson, M. L., Sima, C. S., Chaft, J., Paik, P. K., Pao, W., Kris, M. G., Ladanyi, M., & Riely, G. J. (2013) · Cancer · doi:10.1002/cncr.27730 · Cited by 166
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Villaruz, L. C., & Socinski, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2935 · Cited by 175
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P., & Goldhirsch, A. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.006 · Cited by 172
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Barlesi, F., Scherpereel, A., Gorbunova, V., Gervais, R., Vikström, A., Chouaid, C., Chella, A., Kim, J. H., Ahn, M. J., Reck, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu098 · Cited by 165
Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence
Petersen, L. C., & Mousa, S. A. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-12-0832 · Cited by 165
Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study
Okamoto, I., Yoshioka, H., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Asami, K., Hirashima, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0326 · Cited by 165
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis
Rusthoven, K. E., Hammerman, S. F., Kavanagh, B. D., Birtwhistle, M. J., Stares, M. D., & Camidge, D. R. (2009) · Acta Oncologica · doi:10.1080/02841860802662722 · Cited by 165
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
Goeckenjan, G., Sitter, H., Thomas, M., Branscheid, D., Flentje, M. P., Griesinger, F., Niederle, N., Stuschke, M., Blum, T. G., Deppermann, K., et al. (2010) · Pneumologie · doi:10.1055/s-0029-1243837 · Cited by 166
EGFR, HER2 and VEGF Pathways
Press, M. F., & Lenz, H. (2007) · Drugs · doi:10.2165/00003495-200767140-00006 · Cited by 172
Targeted therapies for non-small cell lung cancer
Dempke, W. C. M., Sütö, T., & Reck, M. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.10.012 · Cited by 165
Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study
Sánchez-Lara, K., Turcott, J. G., Juárez, E., Guevara‐Ramírez, P., Núñez-Valencia, C., Oñate-Ocaña, L. F., Flores, D., & Arrieta, O. G. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.668744 · Cited by 164
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H. N., Nilsson, M. B., Oborn, C. J., Park, Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 166
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Román, J. S., Morante, Z., Araujo, J. M., Gómez, H., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 167
Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review
Henriksson, R., Asklund, T., & Poulsen, H. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0565-x · Cited by 164
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 172
Angiogenesis as a strategic target for ovarian cancer therapy
Spannuth, W. A., Sood, A. K., & Coleman, R. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1051 · Cited by 162
Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma
Zhu, A. X., Holalkere, N.-S., Muzikansky, A., Horgan, K. E., & Sahani, D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0174 · Cited by 161
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
Zinner, R., Obasaju, C. K., Spigel, D. R., Weaver, R., Beck, J. T., Waterhouse, D. M., Modiano, M., Hrinczenko, B. W., Nikolinakos, P. G., Liu, J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000366 · Cited by 161
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer
Zhao, M., Gao, F.-H., Wang, J.-Y., Liu, F., Yuan, H.-H., Zhang, W.-Y., & Jiang, B. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.002 · Cited by 161
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
Mitchell, A., Adams, L. A., MacQuillan, G. C., Tibballs, J. M., Driesen, R. V., & Delrivière, L. (2008) · Liver Transplantation · doi:10.1002/lt.21417 · Cited by 161
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
Estimating Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer
Veronesi, G., Maisonneuve, P., Bellomi, M., Rampinelli, C., Durli, I., Bertolotti, R., & Spaggiari, L. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-11-201212040-00005 · Cited by 160
The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses
Moens, S., Goveia, J., Stapor, P. C., Cantelmo, A. R., & Carmeliet, P. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.009 · Cited by 165
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
Spigel, D. R., Burris, H. A., Greco, F. A., Shipley, D. L., Friedman, E. K., Waterhouse, D. M., Whorf, R. C., Mitchell, R. B., Daniel, D. B., Zangmeister, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7678 · Cited by 159
Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer
Crabb, S. J., Patsios, D., Sauerbrei, E. E., Ellis, P. M., Arnold, A., Goss, G. D., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2545 · Cited by 159
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
Golfinopoulos, V., Salanti, G., Pavlidis, N. A., & Ioannidis, J. P. A. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70281-4 · Cited by 161
Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors
Homsi, J., & DAUD, A. I. (2007) · Cancer Control · doi:10.1177/107327480701400312 · Cited by 166
EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story
Sequist, L. V. D., & Lynch, T. J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.59.090506.202405 · Cited by 156
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
Varricchi, G., Ameri, P., Dessalvi, C. C., Ghigo, A., Madonna, R., Marone, G., Mercurio, V., Monte, I. P., Novo, G., Parrella, P., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00167 · Cited by 167
Molecular aspects of tumour hypoxia
Rademakers, S. E., Span, P. N., Kaanders, J. H. A. M., Sweep, F. C. G. J., van der Kogel, A. J., & Bussink, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.03.006 · Cited by 158
First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis
Goldstein, D. A., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., El‐Rayes, B. F., & Flowers, C. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4904 · Cited by 156
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
O’Connor, J. P. B., Carano, R. A. D., Clamp, A. R., Ross, J., Ho, C., Jackson, A., Parker, G. J. M., Rose, C. J., Peale, F. V., Jr., Friesenhahn, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0731 · Cited by 157
Treatment of advanced non small cell lung cancer.
Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 161
Cancer Immunotherapy
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 166
The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia
Barlow, G. D., Nathwani, D., & Davey, P. (2006) · Thorax · doi:10.1136/thx.2006.067371 · Cited by 157
Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment
Akiyama, K., Ohga, N., Hida, Y., Kawamoto, T., Sadamoto, Y., Ishikawa, S., Maishi, N., Akino, T., Kondoh, M., Matsuda, A., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.029 · Cited by 154
Microenvironment and Radiation Therapy
Yoshimura, M., Itasaka, S., Harada, H., & Hiraoka, M. (2012) · BioMed Research International · doi:10.1155/2013/685308 · Cited by 155
Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)
Katoh, M. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1444 · Cited by 159
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Hamberg, P., Verweij, J., & Sleijfer, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0274 · Cited by 155
Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab
Sandler, A. B., Schiller, J. H., Gray, R. J., Dimery, I. W., Brahmer, J. R., Samant, M. K., Wang, L. I., & Johnson, D. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2412 · Cited by 154
Self-citation
The Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 154
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Crinò, L., Bronte, G., Bidoli, P., Cravero, P., Minenza, E., Cortesi, E., Garassino, M. C., Proto, C., Cappuzzo, F., Grossi, F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.025 · Cited by 153
Vascular endothelial growth factor: Biology and therapeutic applications
Ho, Q. T., & Kuo, C. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.010 · Cited by 155
Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer
Seiwert, T. Y., Haraf, D. J., Cohen, E. E. W., Stenson, K. M., Witt, M. E., Dekker, A., Kocherginsky, M., Weichselbaum, R. R., Chen, H. X., & Vokes, E. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1706 · Cited by 153
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. E. D. C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123626 · Cited by 160
Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles
Li, S., Zhang, Y., Ho, S., Li, B., Wang, M., Deng, X., Yang, N., Liu, G., Lu, Z., Xu, J., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0573-2 · Cited by 154
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
Nimeiri, H. S., Oza, A. M., Morgan, R. J., Friberg, G. R., Kasza, K., Faoro, L. N., Salgia, R., Stadler, W. M., Vokes, E. E., & Fleming, G. F. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.009 · Cited by 152
Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors
Bokstein, F., Shpigel, S., & Blumenthal, D. T. (2008) · Cancer · doi:10.1002/cncr.23401 · Cited by 152
Is Anticancer Drug Development Heading in the Right Direction?
Hambley, T. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3786 · Cited by 153
Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond
Mittal, K., Ebos, J. M. L., & Rini, B. I. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.007 · Cited by 153
Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy
Sato, N., Yamabuki, T., Takano, A., Koinuma, J., Aragaki, M., Masuda, K., Ishikawa, N., Kohno, N., Ito, H., Miyamoto, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3879 · Cited by 156
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
Takeda, M., & Nakagawa, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010146 · Cited by 154
Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501
Horn, L., Dahlberg, S. E., Sandler, A. B., Dowlati, A., Moore, D. F., Murren, J. R., & Schiller, J. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7545 · Cited by 150
Self-citation
Neuropilins: expression and roles in the epithelium
Wild, J. R. L., Staton, C. A., Chapple, K. S., & Corfe, B. M. (2012) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2012.00810.x · Cited by 161
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 152
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor
Hsu, J. Y., & Wakelee, H. A. (2009) · BioDrugs · doi:10.2165/11317600-000000000-00000 · Cited by 148
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
Argiris, A. E., Kotsakis, A. P., HOANG, T. N., Worden, F. P., Savvides, P. S., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds245 · Cited by 148
Antiangiogenic therapy—evolving view based on clinical trial results
Jayson, G. C., Hicklin, D. J., & Ellis, L. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.8 · Cited by 149
Anlotinib as a molecular targeted therapy for tumors (Review)
Gao, Y., Liu, P., & Shi, R. (2020) · Oncology Letters · doi:10.3892/ol.2020.11685 · Cited by 149
Disrupting established tumor blood vessels
McKeage, M. J., & Baguley, B. C. (2010) · Cancer · doi:10.1002/cncr.24975 · Cited by 148
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
Zimmermann, S., Dziadziuszko, R., & Peters, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.005 · Cited by 147
Targeting immune suppressing myeloid-derived suppressor cells in oncology
Kao, J., Ko, E. C., Eisenstein, S. G., Sikora, A. G., Fu, S., & Chen, S. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.02.004 · Cited by 147
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
Maj, E., Papiernik, D., & Wietrzyk, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3709 · Cited by 147
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 149
Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R. D., Aftab, B. T., Huang, P., & Liu, J. O. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c3950 · Cited by 148
Self-citation
Glioblastoma-derived Tumor Cells Induce Vasculogenic Mimicry through Flk-1 Protein Activation
Francescone, R., Scully, S. J., Bentley, B., Yan, W., Taylor, S. L., Oh, D. S., Moral, L. A., & Shao, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334540 · Cited by 147
Metastatic Breast Cancer: The Treatment Challenge
Jones, S. E. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.025 · Cited by 144
Targeting cell signaling pathways for drug discovery: An old lock needs a new key
Aggarwal, B. B., Sethi, G., Baladandayuthapani, V., Krishnan, S., & Shishodia, S. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21500 · Cited by 144
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
Santini, D., Barni, S., Intagliata, S., Falcone, A., Ferraù, F., Galetta, D., Moscetti, L. I., Verde, N. M. L., Ibrahim, T., Petrelli, F., et al. (2015) · Scientific Reports · doi:10.1038/srep18670 · Cited by 144
Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer
Liang, P., Ballou, B. T., Lv, X., Si, W., Bruchez, M. P., Huang, W., & Dong, X. (2021) · Advanced Materials · doi:10.1002/adma.202005155 · Cited by 150
The role of angiogenesis in solid tumours: An overview
Makrilia, N., Lappa, T., Xyla, V., Nikolaidis, I., & Syrigos, K. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.07.009 · Cited by 145
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.239 · Cited by 145
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 144
Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis
Liu, L., Bai, H., Wang, C., Seery, S., Wang, Z., Duan, J., Li, S., Xue, P., Wang, G., Sun, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.016 · Cited by 140
Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
Belani, C. P., Ramalingam, S. S., Perry, M. C., LaRocca, R. V., Rinaldi, D. A., Gable, P. S., & Tester, W. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1912 · Cited by 142
Self-citation
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population
Pallis, A. G., Gridelli, C., van Meerbeeck, J. P., Greillier, L., Wedding, U., Lacombe, D., Welch, J., Belani, C. P., & Aapro, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp360 · Cited by 142
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Falcón, B. L., Chintharlapalli, S. R., Uhlik, M. T., & Pytowski, B. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.001 · Cited by 144
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., Jackson, A. L., Nikolinakos, P., Ospina, B., Naumov, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38443 · Cited by 141
Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
Gerber, D. E., & Schiller, J. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7459 · Cited by 141
Self-citation
Current Treatments for Advanced Stage Non-Small Cell Lung Cancer
Stinchcombe, T. E., & Socinski, M. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-110lc · Cited by 141
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Hirsh, V., Paz-Ares, L. G., Boyer, M. J., Rosell, R., Middleton, G., Eberhardt, W., Szczęsna, A., Reiterer, P., Saleh, M. N., Arrieta, O. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8971 · Cited by 141
Self-citation
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes
Schutz, F. A. B., Je, Y., Azzi, G., Nguyen, P. L., & Choueiri, T. K. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq587 · Cited by 142
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 145
Mechanisms of resistance to anti-angiogenesis therapies
Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 147
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.001 · Cited by 145
Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer
Altorki, N. K., Lane, M. E., BAUER, T. L., Lee, P. C., Guarino, M. J., Pass, H. I., Felip, E., Peylan‐Ramu, N., Gúrpide, A., Grannis, F. W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9749 · Cited by 139
Treatment of Lung Cancer
Gadgeel, S. M., Ramalingam, S. S., & Kalemkerian, G. P. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.003 · Cited by 144
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
Li, F., Zhao, C., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28261 · Cited by 139
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports
Shukuya, T., Takahashi, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01887.x · Cited by 137
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Shaked, Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.57 · Cited by 137
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
Duda, D. G., Jain, R. K., & Willett, C. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3985 · Cited by 138
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
Lalami, Y., & Klastersky, J. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.005 · Cited by 138

Authors: Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H.
Affiliations: Vanderbilt University (US)
Dana-Farber Cancer Institute (US)
University of Missouri (US)
Johns Hopkins University (US)
University of Wisconsin–Madison (US)
University Hospitals of Cleveland (US)
ORCID: Sandler, Alan
Gray, Robert
Brahmer, Julie
Schiller, Joan H.
Dowlati, Afshin
Johnson, David H.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-12-14
Volume: 355
Issue: 24
Pages: 2542-2550
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa061884
OpenAlex: W2145835533
Cited by: 5,761
References: 24
Citations by year: 2026: 49 · 2025: 71 · 2024: 112 · 2023: 135 · 2022: 177 · 2021: 183 · 2020: 180 · 2019: 227 · 2018: 257 · 2017: 278 · 2016: 321 · 2015: 389 · 2014: 400 · 2013: 461 · 2012: 513
FWCI: 299.17
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (U10CA066636, CA-23318, CA49957, U10CA016116, CA66636, U10CA012046, U10CA014548, CA-16116, CA14548, U10CA031946, CA21076, U10CA049957, U10CA021076, U10CA023318, U10CA021115, CA 21115, CA-31946, CA12046)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, bevacizumab, paclitaxel, carboplatin, combination chemotherapy, vascular endothelial growth factor inhibition, overall survival, progression-free survival, pulmonary hemorrhage
MeSH terms: Bevacizumab, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Paclitaxel, Disease-Free Survival, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks